438 research outputs found
PHP128 – Assessing The Impact Of A Multi-Million Public-Private Partnership For Translational Research: The Centre For Translational Molecular Medicine (Ctmm)
Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing IIIV-1
Enhancement of virus infectivity after sCD4 treatment has been documented for SIVagm and HIV-2. It has been suggested that a similar phenomenon may play a role in HIV-1 infection. In the present study we have analysed biological activities of virus neutralizing polyclonal and monoclonal human antibodies and of sCD4, towards HIV-1 chimeras with envelope proteins derived from one donor, which display different biological phenotypes. The antibodies, which recognize the V3 and/or the CD4 binding domains of the glycoproteins of these viruses and also sCD4 showed different levels of virus neutralizing activity toward the syncytium inducing HIV-1 strains. In contrast, they all dramatically enhanced the infectivity of an HIV-1 chimera with an envelope glycoprotein displaying the non-syncytium-inducing phenotype. Given the relatively conserved nature of non-syncytium-inducing HIV-1 surface glycoproteins early after infection, these data suggest a major role for antibody mediated enhancement of virus infectivity in the early pathogenesis of HIV-1 infection
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro
A generic control architecture for material handling systems applied to a baggage handling system
This paper is part of research on generic planning and control of automated Material Handling Systems (MHSs) in different industrial sectors. We build upon previous work to provide a proof of concept for the applicability of a generic control architecture on a specific MHS. To this end, the baggage handling system (BHS) of a major European hub represents our business case. We present the control architecture and apply it to the BHS under study in a simulation environment. This application shows how the generic control architecture adapts to the specificities of this BHS and how it handles unconventional workstation types, i.e., robots. Finally, we highlight the lessons learned and make recommendations for future applications
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro
PHP128 – Assessing The Impact Of A Multi-Million Public-Private Partnership For Translational Research: The Centre For Translational Molecular Medicine (Ctmm)
A dynamic programming heuristic for vehicle routing with time-dependent travel times and required breaks
Drug users' participation in a free hepatitus B vaccination program:Demographic, behavioral, and social-cognitive dterminants
CD4 T cells remain the major source of HIV-1 during end stage disease.
OBJECTIVE: To assess the source of HIV-1 production in lymphoid tissue biopsies from HIV-infected patients, with no prior anti-retroviral protease inhibitor treatment, with a CD4 cell count > 150 x 10(6)/l (group I) or < 50 x 10(6)/l (group II), co-infected with Mycobacterium tuberculosis or Mycobacterium avium complex. DESIGN AND METHODS: Lymphoid tissue biopsies from 11 HIV-1-infected patients, taken for diagnostic purposes, were studied by HIV-1 RNA in situ hybridization and immunohistochemistry. RESULTS: Patients of group I showed well organized granulomas, in contrast with patients of group II, in which granuloma formation was absent. HIV-1 RNA-positive cells in group I patients were found mainly around the granulomas, whereas in group II HIV-1-producing cells were confined to areas with remaining intact lymphoid tissue. Despite the abundant presence of macrophages, the productively infected HIV-1-positive cells in both groups were almost exclusively CD4 T cells. CONCLUSION: In contrast with previously published data, CD4 T cells appear to remain the major source of HIV-1 production in end-stage disease
- …